Loading...
Molecular and immune biomarker testing in squamous-cell lung cancer: effect of current and future therapies and technologies.
Hirsch, F Kerr, K Bunn, P Kim, E Obasaju, C Pérol, M Bonomi, P Bradley, J Gandara, D Jett, J
Hirsch, F
Kerr, K
Bunn, P
Kim, E
Obasaju, C
Pérol, M
Bonomi, P
Bradley, J
Gandara, D
Jett, J
Citations
Altmetric:
Abstract
Patients with non-small-cell lung cancer, including squamous-cell lung cancer (SqCLC), typically present at an advanced stage. The current treatment landscape, which includes chemotherapy, radiotherapy, surgery, immunotherapy, and targeted agents, is rapidly evolving, including for patients with SqCLC. Prompt molecular and immune biomarker testing can serve to guide optimal treatment choices, and immune biomarker testing is becoming more important for this patient population. In this review we provide an overview of current and emerging practices and technologies for molecular and immune biomarker testing in advanced non-small-cell lung cancer, with a focus on SqCLC.
Description
Date
2018-07
Publisher
Collections
Files
Keywords
Type
Article
Citation
Molecular and immune biomarker testing in squamous-cell lung cancer: effect of current and future therapies and technologies. 2018, 19(4): 331-339 Clin Lung Cancer